Inhibitors of influenza viruses replication

Patent metadata

Field	Value
Publication number	US-9808459-B2
Application number	US-201615299757-A
Country	US
Kind code	B2
Filing date	Oct 21, 2016
Priority date	Jun 17, 2009
Publication date	Nov 7, 2017
Grant date	Nov 7, 2017

Abstract

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I):

or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

First claim

What is claimed is:

1. A method of inhibiting the replication of influenza viruses in a biological sample or in a patient comprising administering to said biological sample or patient an effective amount of a compound having the formula

or a pharmaceutically acceptable salt thereof.

2. A method of inhibiting the replication of influenza viruses in a biological sample or in a patient comprising administering to said biological sample or patient an effective amount of a pharmaceutically composition comprising compound having the formula

or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, vehicle, or adjuvant.

3. A method of reducing the amount of influenza viruses in a biological sample inhibiting the replication of influenza viruses in a biological sample or in a patient comprising administering to said biological sample or patient an effective amount of a compound having the formula

or a pharmaceutically acceptable salt thereof.

4. A method of reducing the amount of influenza viruses in a biological sample or in a patient comprising administering to said biological sample or patient an effective amount of a pharmaceutically composition comprising compound having the formula

or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, vehicle, or adjuvant.

5. The method of any one of claims 1 - 4 , wherein the influenza viruses are influenza A viruses.

6. A method of treating influenza infection in a patient, comprising administering to said patient an effective amount of a compound having the formula

or a pharmaceutically acceptable salt thereof.

7. A method of treating influenza infection in a patient, comprising administering to said patient an effective amount of a pharmaceutical composition comprising a compound having the formula

or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, vehicle, or adjuvant.

8. The method of either of claim 6 or 7 , wherein the influenza infection is an influenza A infection.

Assignees

• Vertex Pharma

Inventors

• Charifson Paul S
• Clark Michael P
• Bandarage Upul K
• Bethiel Randy S
• Court John J
• Deng Hongbo
• Davies Ioana
• Duffy John P
• Farmer Luc J
• Gao Huai
• Gu Wenxin
• Jacobs Dylan H
• Kennedy Joseph M
• Ledeboer Mark W
• Ledford Brian
• Maltais Francois
• Perola Emanuele
• Wang Tiansheng
• Wannamaker M Woods
• Byrn Randal
• Zhou Yi
• Lin Chao
• Jiang Min
• Jones Steven
• Germann Ursula A
• Salituro Francesco G
• Kwong Ann Dak-Yee

Classifications

• A61P31/16

  for influenza or rhinoviruses · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/04

  Immunostimulants · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title